Daiichi Sankyo Company, Limited (DSKYF) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - General Branche. Der Hauptsitz des Unternehmens ist in Tokyo, Japan. Der aktuelle CEO ist Hiroyuki Okuzawa.
DSKYF hat IPO-Datum 2008-06-24, 18,726 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $32.23B.
Daiichi Sankyo Company, Limited is a Tokyo-based pharmaceutical company founded in 1899 that researches, develops, manufactures, and markets a diverse portfolio of prescription and over-the-counter medicines globally. The company's core therapeutic areas include oncology, cardiovascular disease, diabetes, pain management, and infectious disease, with key products such as Enhertu (trastuzumab deruxtecan) for cancer treatment, edoxaban for anticoagulation, and teneligliptin for diabetes management. Beyond pharmaceuticals, Daiichi Sankyo operates across consumer health, vaccines, animal health, cosmetics, and medical devices. The company has established strategic collaborations, including a partnership with Guardant Health to develop companion diagnostics, and maintains a strong commitment to innovation across multiple healthcare segments.
